ArticleCanada communicable disease report = Releve des maladies transmissibles au Canada2014
Enhanced surveillance of invasive meningococcal disease in Canada, 2006-2011.
Article in Canada communicable disease report = Releve des maladies transmissibles au Canada, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global epidemiology of serogroup Y invasive meningococcal disease: a literature review.Epidemiology and infection · 2024Pooled it
- Need for Invasive Meningococcal Disease Prevention Through Vaccination for Young Children in the Americas.Vaccines · 2025Review
- Geographical and temporal variations of serogroups and clonal types ofJournal of medical microbiology · 2025Article
- Preventing invasive meningococcal disease in early infancy.Human vaccines & immunotherapeutics · 2022Review
- Epidemiology of invasive meningococcal disease in Canada, 2012-2019.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2022Article
- Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)-Part 2: Inactivated Vaccines.Journal of the Canadian Association of Gastroenterology · 2021Review
- Cost-effectiveness of alternative strategies for vaccination of adolescents against serogroup B IMD with the MenB-FHbp vaccine in Canada.Canadian journal of public health = Revue canadienne de sante publique · 2020Article
- Culture-Confirmed Invasive Meningococcal Disease in Canada, 2010 to 2014: Characterization of Serogroup BmSphere · 2020Article
- Risk Analysis of Eculizumab-Related Meningococcal Disease in Japan Using the Japanese Adverse Drug Event Report Database.Drug, healthcare and patient safety · 2020Article
- Epidemiologic Trends, Global Shifts in Meningococcal Vaccination Guidelines, and Data Supporting the Use of MenACWY-TT Vaccine: A Review.Infectious diseases and therapy · 2019Review
- Increase in ST-11 serogroup WCanada communicable disease report = Releve des maladies transmissibles au Canada · 2019Article
- Healthcare Resource Utilization and Cost of Invasive Meningococcal Disease in Ontario, Canada.The Pediatric infectious disease journal · 2019Observational
- Epidemiology and Control of Meningococcal Disease in Canada: A Long, Complex, and Unfinished Story.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2019Review
- Meningococcal disease in adolescents and young adults: a review of the rationale for prevention through vaccination.Human vaccines & immunotherapeutics · 2019Review
- Update on invasive meningococcal vaccination for Canadian children and youth.Paediatrics & child health · 2018Article
- Increase inCanada communicable disease report = Releve des maladies transmissibles au Canada · 2017Article
- Meningococcal serogroup B vaccines: Estimating breadth of coverage.Human vaccines & immunotherapeutics · 2017Review
- Article
- Invasive serogroup WCanada communicable disease report = Releve des maladies transmissibles au Canada · 2016Article
- Invasive Bacterial Diseases in Northern Canada, 2006-2013.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe purpose of this report is to describe the epidemiology of invasive meningococcal disease (IMD) in Canada from 2006 to 2011.
methodsData from the Enhanced Invasive Meningococcal Disease Surveillance System and national population estimates were selected for descriptive and inferential analyses. The geographic, demographic, seasonal and subtype distributions as well as clinical characteristics of the IMD cases were examined. Incidence and mortality rates were calculated per 100,000 population per year; 95% confidence intervals (CI) were calculated for rate comparison. The direct method was used for age standardization. Proportions were compared using the chi-squared test at a p<0.05 significance level.
resultsDuring the study period, the mean incidence rates of IMD were 0.58 (total), 0.33 (serogroup B), 0.07 (serogroup C), 0.03 (serogroup W-135) and 0.10 (serogroup Y). The median age for serogroups B, C, W-135 and Y was 16, 43, 38 and 47 years respectively. The mean age-specific incidence rates among infants under 1 year of age (7.35, CI: 5.38-9.32) and children from 1 to 4 years of age (1.89, CI: 1.54-2.24) were significantly higher than those in any other age group. The mean case fatality ratio was 8.1% (range 4.3%-14.3%). The average number of cases that occurred per month was significantly higher (p<0.0001) in winter (18 cases) than in summer (12 cases).
conclusionIMD is still endemic in Canada. Although individuals at any age can be affected, infants under 1 year of age are at the greatest risk, followed by children aged 1-4 years and individuals aged 15-19 years. Following the implementation of routine childhood immunization programs with monovalent meningococcal C conjugate vaccines (MenC) in all provinces and territories (beginning in 2007), the incidence of serogroup C has decreased significantly over the study period and is now at an all-time low. Serogroup B is the leading cause of IMD, and diseases of serogroup W-135 and Y have stabilized at relatively lower incidence rates. With the addition of immunization programs using quadrivalent conjugate meningococcal vaccines (MCV4), we would expect further reductions in the incidence of meningococcal infection in Canada.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.